Target Name: SNRPEP4
NCBI ID: G100130109
Review Report on SNRPEP4 Target / Biomarker Content of Review Report on SNRPEP4 Target / Biomarker
Other Name(s): Small nuclear ribonucleoprotein polypeptide E pseudogene 4 | SNRPE pseudogene 4

SNRPEP4: A Potential Drug Target and Biomarker

Sodium channels play a crucial role in many biological processes, including muscle contractions, nerve signaling, and brain function. SNRPEP4, a gene encoding a sodium channel subunit, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders.

SNRPEP4 is a highly conserved gene that is expressed in many tissues, including brain, heart, and muscle. It is a member of the SNRPEP gene family, which is known for its role in generating voltage-dependent sodium channels. SNRPEP4 is expressed in the brain and is involved in the development, maintenance, and regulation of neuronal excitability.

Studies have shown that SNRPEP4 is involved in various physiological processes, including neuronal communication, neurotransmitter release, and synaptic plasticity. It has been shown to play a role in modulating the activity of other genes, including those involved in neurotransmitter release and synaptic plasticity.

As a potential drug target, SNRPEP4 has the potential to treat a variety of neurological and psychiatric disorders. For example, SNRPEP4 has been shown to be involved in the pathophysiology of several psychiatric disorders, including depression, anxiety, and schizophrenia. Studies have shown that SNRPEP4 is expressed in the brains of individuals with these disorders and that modulating its activity may be a promising approach to treating these disorders.

In addition to its potential as a drug target, SNRPEP4 has also been identified as a potential biomarker for several psychiatric disorders. The ability to measure the expression of SNRPEP4 in brain tissue can be used as a diagnostic tool for psychiatric disorders and as a target for therapeutic intervention.

The study of SNRPEP4 has also identified a potential mechanism by which the channel can be modulated. Studies have shown that the activity of SNRPEP4 can be modulated by various factors, including changes in membrane potential and the presence of certain ions. These changes in SNRPEP4 activity can have a significant impact on the activity of other genes involved in neural communication.

Overall, SNRPEP4 is a promising drug target and biomarker for a variety of psychiatric and neurological disorders. Further research is needed to fully understand its role in these conditions and to develop effective treatments based on its modulation. However, the study of SNRPEP4 is a promising area of research that has the potential to advance our understanding of the underlying mechanisms of psychiatric and neurological disorders.

Protein Name: SNRPE Pseudogene 4

The "SNRPEP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNRPEP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

SNRPF | SNRPF-DT | SNRPG | SNRPGP10 | SNRPGP18 | SNRPN | SNTA1 | SNTB1 | SNTB2 | SNTG1 | SNTG2 | SNTG2-AS1 | SNTN | SNU13 | SNUPN | SNURF | SNURFL | SNW1 | SNX1 | SNX10 | SNX10-AS1 | SNX11 | SNX12 | SNX13 | SNX14 | SNX15 | SNX16 | SNX17 | SNX18 | SNX18P23 | SNX18P24 | SNX18P3 | SNX19 | SNX2 | SNX20 | SNX21 | SNX22 | SNX24 | SNX25 | SNX27 | SNX29 | SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2